• Svetlana Blitshteyn and Sera Whitelaw.
• Department of Neurology, State University of New York At Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA. sb25@buffalo.edu.
• Immunol. Res. 2021 Apr 1; 69 (2): 205211205-211.

ObjectiveTo describe clinical features, diagnostic findings, treatments, and outcomes in patients with new-onset postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders following SARS-CoV-2 infection (COVID-19).MethodsWe retrospectively reviewed medical records for patients who presented with persistent neurologic and cardiovascular complaints between April and December 2020 following COVID-19 infection.ResultsTwenty patients (70% female) were included in this study.Fifteen had POTS, 3 had neurocardiogenic syncope, and 2 had orthostatic hypotension. Six patients had abnormalities on cardiac or pulmonary testing, and 4 had elevated autoimmune or inflammatory markers. All patients were treated with non-pharmacologic therapies, and most required pharmacologic therapies. Six to 8 months after COVID-19, 17 (85%) patients had residual autonomic symptoms, with 12 (60%) unable to return to work.ConclusionsPOTS can follow COVID-19 in previously healthy patients. Appropriate diagnostic investigations and therapies are necessary to identify and treat autonomic dysfunction after COVID-19.

This article appears in the collection: Post-COVID POTS (Postural orthostatic tachycardia syndrome).

17 keywords...

hide…